Executive and non-executive directors

Michal Zahradníček, M.Eng., MBA
Chairman of the Board of Trustees

Michal Zahradníček, one of the founders of PrimeCell Therapeutics, is an investor and acts as a key figure in several high-tech companies in the Czech Republic and the Central and Eastern European region. He began his career in 1993, working as an economist for several international companies. Since 2001, he has been involved in investments in areas with high innovation potential. He acted as an advisor of the Ministry of Finance of the Slovak Republic, also taking part in health reform preparations. In 2004, he was awarded the title Manager of the Year for a Medium-Size Company and he was listed among the TOP 10 most successful Czech managers. Michal Zahradníček graduated from the Brno University of Technology. He then continued his studies at the Technical University in Darmstadt in Germany and at the Manchester Metropolitan University in the UK.

Zdeněk Souček, J.D. PhDr, Prof, Sc.
Strategic Planning Consultant

Professor Zdeněk Souček, one of the key figures of PrimeCell Therapeutics, is a Czech specialist renowned for his expertise in the area of strategic management. He is well-known as a successful strategic manager for various medium-size and large enterprises in the Central and Eastern European region. He has attended a large number of international events across 68 countries, making presentations in the areas such as innovation strategy and competitiveness. He is also president of the "Strateg Club". In the meantime, he teaches economics at the University of Economics in Prague and an MBA programme at the Prague International Business School. Professor Souček holds a juris doctor degree from the Charles University in Prague.

MUDr. Elena Šťastná
Member of the Supervisory Board of National Cell and Tissue Centre & 4MEDi – Center of Cell Therapies and Diagnostics (CBTD)

Dr. Elen Šťastná graduated from Charles University in Hradec Kralové in general medicine. After obtaining a first degree specialization in the field of general medicine she worked in this field until 2000. She has been involved in the projects of preventive medicine and projects aimed at improving the quality of life. She has worked at the Danish pharmaceutical and nutraceutical company Pharma Nord at managerial position in the field of education. Dr. Šťastná also provides consulting and advisory services in marketing communications activities, strategic planning and PR. She is The President of Soroptimist International Prague-world, prestigious women's organizations with direct access to the UN and other international organizations, such as UNESCO and the Council of Europe. Soroptimist International seeks to improve access to health care, doctors, midwives and applies to the fight against the spread of AIDS and transmission of the disease from mother to newborn and improvement of living conditions of women and children.

Dr. Štastná is the founder of the AA Homolka Club at the Department of Pediatric Allergy and Clinical Immunology Hospital Homolka, whose activities contribute to the improvement of awareness and better care for children with allergy and asthma.

Petr Koška, M.Eng., MBA
Chief Executive Officer

Petr Koška is Chief Executive Officer of PrimeCell Therapeutics Inc. and Vice-Chairman of the Board of Directors of the National Cell and Tissue Centre Inc. (one of the subsidiaries of PrimeCell Therapeutics). He joined PrimeCell Therapeutics in January 2013 holding a variety of leadership positions over the course of his career. Mr Koska is a well-known professional within the healthcare industry in the Czech Republic. He is a respected manager, who boasts of many years of experience leading large medical facilities.

Prior to his position in PrimeCell Therapeutics, since 2008 he was Chief Executive Officer at one of the largest university hospitals in the Czech Republic, namely, St. Anne´s University hospital Brno. In his previous position he gained knowledge of transferring medical science and research into clinical practice. Additionally, he was the head of a unique team of professionals who were involved with the development of an international centre of clinical research within the premises of St. Anne´s hospital, namely, International Clinical Research Center (ICRC). This centre was developed in co-operation with Mayo Clinic, Rochester, Minnesota, USA.

He started his professional career in 1996 at the University hospital Brno, where he held various leading positions until 2007, when he was elected General Director. In 1997 - 1998 he was one of the three key figures involved in the most unique plan in the healthcare industry in the Czech Republic up-to-date, which was the merger of university hospitals in the Brno region.

Mr Koška graduated at the Technical University Brno. Later, he obtained the MBA degree at Prague International Business School. Currently he is the candidate for PhD in business (DBA). In 2008 - 2012 he was a member of the scientific committee at the Medical faculty of Masaryk University in Brno.

Petr Čumba, M.Eng.
Chief financial officer

Ing. Petr Čumba graduated in the Brno University of Technology and in the course of his career, he held management positions in financial institutions, trading and manufacturing companies. Coming from a group SAB Finance – MPU, where was working as a chief financial officer in 2013-2016, he stood at the preparation of the transformation of MPU to a bank and ensure the implementation of new European legislation for the financial sector to internal processes. During his work for both companies there has been negligible growth in their profitability.

In 2010-2012 he was responsible for the financial management of manufacturing companies BONATRANS GROUP and MANEX Industrial Automation, where he led the crisis management team that has successfully completed the reorganization of the company.

Until 2009, he worked nearly 15 years in companies operating in oil and gas division of the KKCG Group. The longest in the MND, the biggest Czech oil and gas producer, where in addition to membership in the company boards, he managed finances in the parent company and subsidiaries. He was responsible for all standard economic activities, cash flow management in the group, both internal and external financing, management of domestic and foreign subsidiaries, development of gas trading after the end of state regulation, sales of crude oil, implementation of system of central purchasing, several transformations of companies in the group and other related activities.

Ing. Pavel Markalous
Director of the Scientific and Technological park 4Medical Innovations in Ostrava

Ing. Pavel Markalous is since 2015 director of scientific and technological park 4Medical Innovations in Ostrava and is responsible for its operation and development.

It is also responsible for ensuring technical support and research activities carried out in the areas of scientific and technological park. Ing. Markalous has large experience from top management. He gained experience as a manager in several IT companies in the implementation of ERP systems. Such knowledge of business processes has expanded the area of management consulting and management development support. From 2004 he worked at Webcom Inc. (Now Konica Minolta), as project manager, and from 2006 to 2012, he held the position of CEO and Chairman of the Board. From 2012 to 2015 he worked as a business consultant and project managed the development of the distribution network in Central Europe.

Ing. Markalous graduated from the Military Technical School in Liptovský Mikuláš in the Slovak Republic in 1993.

Mgr. Igor Hlásenský

Legal matters of PrimeCell Therapeutics are in hands of a team of in-house lawyers led by Igor Hlásenský, young but well-experienced specialist in medical law as well as commercial and administrative law. Upon finishing his studies at the Faculty of Law of Masaryk University in Brno in 2010 he worked for a respected law firm and later moved up to the Ministry of Health to became a main lawyer, inspector, and deputy head of Inspectorate of narcotic drugs and psychotropic substances.

During his career Igor attended many conferences, trained people in legal consciousness and was a part of the European Commission delegation to Serbia for the purpose of bringing this country’s legislation into line with the European law. Igor is a major author of the text of the Czech Act On Drug Precursors and certain other general binding regulations and contributed significantly to terminate complicated and hyped cases.

Nowadays Igor is ranked among leading experts in legal obligations related to handling with tissues and cells and he strongly helps PrimeCell Therapeutics to conclude all the necessary contracts and conduct its activities in full compliance with the law.

RNDr. Eva Matějková
Head of Regulatory Affairs

Eva Matějková received her degree at the Masaryk University Brno in microbiology and molecular biology. As of 2005, she has been involved in the area of research within the field of mesenchymal stem cells and cell cultivations. In the meantime, she has also participated in a variety of clinical studies and for a period of five years she has been working as a research fellow in treatments of leukaemia at the Faculty of Medicine at the Masaryk University Brno. In 2008 she was named the Head of the Cell Therapy Department at Tissue Bank at the University Hospital Brno. Since 2009 she has worked as Qualified Person and in the same year she has been appointed Head of the Department of Cell Transplants at the National Cell and Tissue Centre. She is also responsible for clinical trials.
Actively participating at national and international conferences, presenting new research findings, Eva Matějková is a renowned professional within the field of Advanced Therapies.

MUDr. Serhiy Forostyak, Ph.D.
Head of Experimental Laboratory

Dr. Forostyak has graduated from a Faculty of Medicine at Ternopil’ State Medical University, Ukraine in 2005 (with honours). After receiving his first degree specialization in the field of general surgery (2008) Dr. Forostyak has continued his education at the 2nd Faculty of Medicine at Charles University in Prague and Institute of Experimental Medicine at Czech Academy of Sciences.

He has defended his doctoral thesis in 2012 and received a title PhD in Neuroscience. During his doctoral and postdoctoral years he has received several prestigious fellowships and awards (CORTEX: Marie Curie Early Stage Training Net; FENS Young Investigator Training Program; Czech Neuroscience Society award for best publication published by a Young Neuroscientist; Development of Research Teams for the BIOCEV; EUROCELLNET travel fellowship etc.) and underwent internship in prestigious universities (Cambridge University, UK; Katholieke Universiteit Leuven, Belgium; Neuroscience Institute Cavalieri Ottolenghi, Italy; University of Pittsburgh, USA). Dr. Forostyak’s research lays in the field of regenerative and translational medicine with a main focus on evaluation of regenerative potential of stem cells (mesenchymal stromal cells; embryonic stem cells; induced pluripotent stem cells etc.) and biomaterials, and their application to cure neurotrauma and neurodegenerative disorders. Current scientific record includes 22 publications (WOS) in prestigious international peer-reviewed journals, 3 book chapters and 3 papers are currently in press. Dr. Forostyak has been principal/co-principle investigator in several research projects. He is acting as a scientific evaluator of national and international grant agencies, but also contributes as a reviewer in prestigious scientific journals. He has been actively participating at numerous national and international conferences, but also acted as an organising committee member at several international meetings.


PrimeCell Therapeutics a.s. je biotechnologická společnost vyvíjející léčivé přípravky z lidských buněk s cílem zlepšit kvalitu lidského života. Využíváme přirozené léčivé a regenerativní vlastnosti buněk. Speciálními manipulacemi ovlivňujeme vlastnosti buněk tak, aby léčebného účinku bylo dosaženo v postižených tkáních.



Využíváme přirozených léčivých a regenerativních vlastností buněk a jejich součástí. Speciálními ověřenými postupy ovlivňujeme vlastnosti buněk tak, abychom dosáhli léčebného účinku v postižených tkáních.

PrimeCell Therapeutics a.s. poskytuje pacientům nové metody vysoce personalizované efektivní léčby, které využívají lidské buňky a tkáně a to především v případech, kdy stav pacientů nelze léčit běžnými léčivy nebo jinou konvenční metodou, či je-li léčba lidskými buňkami pro pacienta šetrnější. Bude se věnovat především přípravě autologních a alogenních léčivých přípravků pro ortopedické indikace, ischemické choroby, kožní defekty nebo hojení ran.


Jedním ze základů aktivit PrimeCell Therapeutics a.s je intenzivní spolupráce s renomovanými tuzemskými a světovými vědeckými institucemi a klinickými centry s cílem využít výsledky základního výzkumu v klinické praxi, a to co nejrychleji ku prospěchu pacientů. Dále bude rozvíjena dosavadní síť více než sto klinických center a partnerů v České republice a v zahraničí.


PrimeCell Therapeutics a.s. byl založen v roce 2007. Je jedním z nejvýznamnějších investorů v Evropě v oblasti regenerativní medicíny. Vlastní a provozuje vysoce moderní vývojovou a výrobní infrastrukturu pro aplikovaný vývoj, zpracování a výrobu lidských buněk a tkání. Ve svém portfoliu má téměř 8000 m2 laboratorních prostor, z toho 2000 m2 cGMP zázemí pro vývoj a výrobu buněčných a tkáňových produktů. Více o infrastruktuře PrimeCell Therapeutics a.s. naleznete na www.natic.cz a www.4medi.cz


  About us
who we are
corporate Overview executive
and non-executive

our history
partnerships and our
Advanced & Cell Therapy

Key programs & products
current products
products in the pipeline
our innovative strategy
research areas
our developments
co-operation opportunites
PrimeCell in media
odborné publikace
corporate identity
About 4MEDi

Contact us
contact us
informace pro akcionáře
PrimeCell Therapeutics a.s.
Sídlo: Jáchymova 26/2 Praha 1/ 110 00
Office: U Plynárny 1002/97 Praha 10/ 101 00

Praha / Brno / Ostrava / New York / Singapore / Jeddah
© by primecell | pupečníková krev | design by upsala